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ited moderate decrease in VIII:C level, one case manifested slight
decline in physical ability, one case manifested slight decline in
joint function. Meanwhile, both the decreasing of HIV RNA load
and the increasing of CD4+ T cell count were notable (P<0.05). It
is showed no statistics change could be seen in complete blood
cell count after 6 years of HAART, however, the mean hemoglobin
level of all 39 patients had decreased slightly blow normal range.
It also showed, serum alanine aminitransperase (ALT) increased
to a level which moderately above normal span but without
statistics signiﬁcance, however, triglyceride and uric acid were
markedly higher compared with the data before HAART (P<0.05);
no statistics difference could be seen in aspartate transaminase
(AST), serum bilirubin (SB), blood amylase, blood urea nitrogen,
blood creatinine and fasting plasma glucose (P>0.05).
Conclusion: Long term HAART is likely to have limited im-
pact on haemorrhage status, joint function and physical ability
in Haemophilia A/AIDS patients; however, HAART therapy is
effective to inhibit HIV replication and promote CD4+ cells prolif-
eration which indicates HAART is positive for immune recovery,
moreover, Long term HAART could induce animia, hepatic dam-
age, hyperlipidemia and hyperuricemia and which may widely
exist.
CS11-03 Promoting HIV Screening and Voluntary
Counselling and Testing as Important Public
Health Interventions
David P. Wilson*. National Centre in HIV Epidemiology and
Clinical Research, University of New South Wales
Aims: Individuals who are diagnosed as HIV-positive tend to
change behavior to reduce transmission to others. The aims of
this work are to estimate the expected epidemiological impacts
of increasing HIV testing rates; to determine what testing levels
are required for serosorting to be an effective risk reduction
strategy for HIV-negative individuals; and to recommend optimal
testing rates for different settings and epidemics.
Methods: Extensive reviews were carried out of the social-
behavioral, biological, clinical, and epidemiological HIV litera-
ture relevant to numerous countries. These diverse data sources
were incorporated into mathematical models that simulated
complex mixing patterns and polymorphous sexual and injecting
behaviors among numerous population subgroups, the transmis-
sion of HIV throughout the population, along with tracking of
the disease progression and clinical outcomes of HIV-infected
individuals. The models were used to simulate the past and cur-
rent trends of HIV epidemics, identify key drivers, and forecast
expected future trends according to current conditions and due
to implementation of targeted intervention strategies focused
on voluntary counseling and testing (VCT) and routine screen-
ing. The models were coupled with uncertainty and sensitivity
analyses.
Results: There is a disproportionate association between undiag-
nosed status and HIV transmission. For example, it is estimated
that in Australia, where testing rates are relatively high, ap-
proximately 30% of new HIV infections are transmitted from the
∼10-15% of HIV infections that are undiagnosed. Similar dispro-
portionate associations exist in other locations. Even modest
increases in HIV testing rates could have substantial epidemi-
ological consequences in all settings, particularly in countries
where rates are currently low.
Surprisingly, it was found that the practice of serosorting to
reduce the risk of HIV acquisition likely increases the risk of HIV
in most settings; testing rates would need to be sufﬁciently high
such that the proportion of infections that are undiagnosed is
less than 20% for serosorting to be effective.
The appropriate goals for testing frequency and coverage rates
vary considerably between locations. However, increases in cov-
erage among the right target groups, if accompanied by even
relatively small behavior change, can be sufﬁcient to lead to sig-
niﬁcant public health control of HIV epidemics. In most settings,
public health goals should be at least regular annual testing of
individuals at relatively high risk and up to 4 times per year
for individuals at very high risk of HIV infection. Testing-based
interventions can be expected to have a noticeable impact within
a few years and the beneﬁts will also increase over time.
Conclusions: Promoting increases in the coverage and frequency
of HIV testing, particularly among people at high risk, could
be a highly-effective public health intervention. It is important
to provide easy access to VCT sites and make HIV screening a
more regular and routine component of clinical consultations.
This must be coupled with educational messages that encour-
age testing and make it more acceptable within given cultural
environments.
CS11-04 Sustaining First-line Antiretroviral Regimens:
The Third World Experience
Christopher K.C. Lee*. Infectious Diseases Unit, Sungai Buloh
Hospital, Malaysia
Long-term success with Highly Active Antiretroviral therapy
(HAART) is a realistic and achievable goal for people living with
HIV-1 infection even in resource limited settings. There is now
ever growing evidence of continuing improvements in the clinical
management and treatment outcomes of people living with HIV-1
infection. This has facilitated our understanding of the contribut-
ing factors that determine durable success. The epidemiologic
evidence of success with HAART in suppressing HIV-1 replication
and preventing AIDS progression and death is now overwhelming.
Walensky et al estimated that 2.3 million life-years were saved
by antiretroviral therapy in the United States from 1996-2004.
A key determinant in ensuring long-term success is the selec-
tion of the initial antiretroviral regimen. The “ideal” regimen
should have high potency, convenient dosing, and minimal short
as well as long-term adverse effects. Of equal importance is the
timeliness of treatment initiation which has been recommended
to commence before the development of AIDS deﬁning events.
Various strategies to ensure optimal medication adherence and
patient participation has been utilized to maximize good clinical
outcome. These adherence programs must be consistent and
acceptable to local culture and practice. Often family and com-
munity support has been used as tools to achieve good medical
adherence. This is of particular importance in countries with
limited second-line antiretroviral options; where most patients
realistically have but one therapeutic chance to achieve good and
sustained viral suppression. Speciﬁc attention to comorbidities
including drug use, that may affect treatment outcomes must
also be considered and addressed. The HAART experience from
countries with limited resources will be discussed to illustrate
the above key information.
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The world’s ﬁrst nationwide hepatitis B virus (HBV) universal vac-
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cination program for infants was launched in Taiwan in July, 1984.
Pregnant women were screened for serum HBsAg. Infants of high-
risk mothers with positive HBeAg received HBIG within 24 h of
birth in addition to vaccines. All infants received 3 doses (at 0, 1
and 6 months of age) of recombinant HBV vaccines. All of the vac-
cines and HBIG given to the infants were paid for by the govern-
ment. HBV vaccination coverage rate is as high as 97% at present.
Following the universal hepatitis B virus (HBV) vaccination pro-
gram for infants in Taiwan 25 years ago, HBsAg sero-prevalence
declined from about 10% to 0.6% in children under 15 years old in
Taipei city during the past two decades. The sero-positive rates
for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and 3.7%,
respectively, in those born after the vaccination program (<20
years old) in 2004.
The institution of universal HBV vaccination decreases the in-
cidence of HCC in children. From 1981 to 1994, the incidence
of HCChepatocellular carcinoma in children 6 to 9 years of age
declined from 0.52/100,000 for those born between 1974 and
1984 to 0.13 for those born between 1984 and 1986 (P<0.001)
in Taiwan. Later on, we extended the follow-up to 2000, the
incidence of HCC per 100,000 children declined from 0.54 to 0.20
in those born before versus after the vaccination program.
A positive maternal HBsAg status was found in 89% of the HB-
sAg sero-positive subjects born after the vaccination program.
In spite of the success of hepatitis B immunization, childhood
HCC still failed to be completely eradicated by the universal
vaccination program. This is evidenced by the very high HBsAg
sero-positive rate in our HCC children (97%) and their mothers
(96%).
The prevalence and clinical signiﬁcance of the mutations in the
a determinant (amino acids 121–149) of HBsAg was not well elu-
cidated, particularly in the post-vaccination era. The prevalence
of a determinant mutants in HBV-DNA positive children was 7.8%
(8/103) in 1984, signiﬁcantly increased to 19.6% (10/51) in 1989,
peaked at 28.1% (9/32) in 1994, and remained at 23.1% (3/13) in
1999; it was higher in those fully vaccinated compared with those
not vaccinated (15/46 vs. 15/153; p<,0.001). However, the num-
ber of mutant infected children in each survey was stable. The
other group of subjects who are susceptible to vaccine failure is
the immune- compromized hosts.
In conclusion, universal HBV vaccination provides long-term pro-
tection up to 20 years, and a universal booster is not indicated
for the primary HBV vaccinees before adulthood. Mother-to-child
transmission is the primary reason for vaccine failure and needs
to be tackled in future vaccination programs. The emergence
of escape mutant did not impose any increased risk of chronic
infection at this moment. The development of new vaccines is
expected to overcome the vaccine failure.
CS12-03 Hepatitis B Virus Genetic Variability and its
Clinical Signiﬁcance
Hong Tang*. Department of Infectious Diseases, West China
Hospital of Sichuan University, Chengdu, Sichuan, PR China
Hepatitis B virus (HBV) infection is a worldwide health problem
and the major cause of chronic hepatitis, cirrhosis as well as
hepatocellular carcinoma (HCC). HBV is an enveloped virus, con-
taining a 3.2 kb partially double-stranded DNA genome that is
replicated via an RNA intermediate using its own encoded re-
verse transcriptase (RT). The HBV RT does not have proofreading
or editing activity, therefore, together with its enormous daily
virion production, errors inevitably occur during replication in
long-term infected patients. Particular selection pressures, both
endogenous (host immune clearance) and exogenous (vaccine or
antivirals), strongly in?uence the predominant HBV quasispecies
and their biological characteristics in an infected individual at
a given time point. The mutation of HBV would bring a series
of new problems to the prevention, diagnosis and treatment of
chronic hepatitis B.
Current studies have showed that mutations in the genome
exert a substantial effect on the replication capacity of the
virus. Immune and antiviral selection pressures result in vac-
cine/immunoglobulin escape mutants and antiviral resistant
variants. Viruses encoding changes associated with antiviral
resistance often have reduced replication in vitro, but the ac-
cumulation of additional compensatory mutations helps restore
viral ﬁtness. Additionally, in our study, we found that HBV
genome variation occurred in the hepatocyte nuclear factor
(HNF) 4 and/or HNF3 binding sites may signiﬁcantly change the
capacity of viral replication.
The mechanisms determining the emergence of viral variants
in response to immune selection may be important in consider-
ing possible therapeutic interventions designed to prevent their
pathophysiological consequences. Viral variants containing two
nucleotide substitutions (A1764T and G1766A) in the proximal
nuclear hormone receptor binding site in the nucleocapsid pro-
moter are very common variants identiﬁed from patients who
have seroconversion from HBeAg to anti-HBe antibody status.
The results of our study indicate that replication of wild type
and variant viruses can be differentially regulated by nuclear
hormone receptors, and this may be important in the selection of
speciﬁc viral variants as a result of an antiviral immune response
Chronic HBV infection is a dynamic state involving interaction
between the virus, the hepatocytes and the immune cells of
the host. The role of continuing HBV replication in the hepatic
necroinﬂammatory response leading to hepatocarcinogenesis has
been showed. Several HBV mutant strains including mutations in
precore, core promoter and deletion mutation in pre-S/S genes
have been reported to be associated with the pathogenesis of
progressive liver disease, including hepatitis ﬂare, decompensa-
tion, liver cirrhosis and hepatocellular carcinoma (HCC).
The goal of therapy in patients with chronic hepatitis B is
rapid viral suppression and long-lasting maintenance of unde-
tectable levels of serum HBVDNA. Nucleoside/nucleotide ana-
logues rapidly are becoming the treatment of choice for patients
with Chronic Hepatitis B. The major draw back of this treatment
is the considerable risk of developing antiviral drug resistance as-
sociated with progressive disease, which occurs most frequently
in lamivudine-treated patients,bu talso has been shown for other
agents (eg,adefovir, telbivudine and entecavir) evaluated in
long-term studies. Location of the major antiviral drug-resistant
mutations associated with LMV,LdT,ADV,TDF,and ETV have been
identiﬁed in recent years. Antiviral therapy should be modifed as
soon as resistance is detected.
Therefore, it is necessary to monitor the occurrence and develop-
ment of HBV variations and the relationship between variability
and clinical outcome dynamically. Enhancing the biological char-
acteristics research of hepatitis B virus would help us further
understand the effect of mutations on viral replication capacity,
and better understand the roles of mutations in drug-resistance
and disease prognosis.
CS12-04 Hepatitis B and Transfusion Medicine:
Unexpected Donor Screening Events
F. Blaine Hollinger*. Baylor College of Medicine, Houston, TX,
USA
It is well recognized that the transfusion of blood containing
HBsAg is associated with the development of posttransfusion
hepatitis B. This risk of acquiring an HBV infection underwent
a dramatic reduction with the advent of HBsAg screening of
blood donors in the 1970s in conjunction with the implementa-
tion of an all-volunteer donor population. Subsequent studies in
the 1980s and 1990s implicated high-titered, anti-HBc positive
blood that lacked HBsAg and anti-HBs, in the transmission of
HBV. This prompted the addition of anti-HBc screening of blood
donors in those countries where HBV is not endemic. Later, it was
discovered that the units of blood from these anti-HBc reactive,
